Tacken PJ - Search Results

1

Targeted delivery of TLR ligands to human and mouse dendritic cells strongly enhances adjuvanticity.

Tacken PJ, Zeelenberg IS, Cruz LJ, van Hout-Kuijer MA, van de Glind G, Fokkink RG, Lambeck AJ, Figdor CG. Tacken PJ, et al. Blood. 2011 Dec 22;118(26):6836-44. doi: 10.1182/blood-2011-07-367615. Epub 2011 Oct 3. Blood. 2011. PMID: 21967977 Free article.

2

Effective induction of naive and recall T-cell responses by targeting antigen to human dendritic cells via a humanized anti-DC-SIGN antibody.

Tacken PJ, de Vries IJ, Gijzen K, Joosten B, Wu D, Rother RP, Faas SJ, Punt CJ, Torensma R, Adema GJ, Figdor CG. Tacken PJ, et al. Blood. 2005 Aug 15;106(4):1278-85. doi: 10.1182/blood-2005-01-0318. Epub 2005 May 5. Blood. 2005. PMID: 15878980 Free article.

3

Targeting antigens to dendritic cells in vivo.

Tacken PJ, Torensma R, Figdor CG. Tacken PJ, et al. Immunobiology. 2006;211(6-8):599-608. doi: 10.1016/j.imbio.2006.05.021. Epub 2006 Jul 7. Immunobiology. 2006. PMID: 16920498 Review.

4

Targeting DCIR on human plasmacytoid dendritic cells results in antigen presentation and inhibits IFN-alpha production.

Meyer-Wentrup F, Benitez-Ribas D, Tacken PJ, Punt CJ, Figdor CG, de Vries IJ, Adema GJ. Meyer-Wentrup F, et al. Among authors: tacken pj. Blood. 2008 Apr 15;111(8):4245-53. doi: 10.1182/blood-2007-03-081398. Epub 2008 Feb 7. Blood. 2008. PMID: 18258799 Free article.

5

Targeted PLGA nano- but not microparticles specifically deliver antigen to human dendritic cells via DC-SIGN in vitro.

Cruz LJ, Tacken PJ, Fokkink R, Joosten B, Stuart MC, Albericio F, Torensma R, Figdor CG. Cruz LJ, et al. Among authors: tacken pj. J Control Release. 2010 Jun 1;144(2):118-26. doi: 10.1016/j.jconrel.2010.02.013. Epub 2010 Feb 13. J Control Release. 2010. PMID: 20156497

6

Human plasmacytoid dendritic cells phagocytose, process, and present exogenous particulate antigen.

Tel J, Lambeck AJ, Cruz LJ, Tacken PJ, de Vries IJ, Figdor CG. Tel J, et al. Among authors: tacken pj. J Immunol. 2010 Apr 15;184(8):4276-83. doi: 10.4049/jimmunol.0903286. Epub 2010 Mar 19. J Immunol. 2010. PMID: 20304825

7

Targeted antigen delivery and activation of dendritic cells in vivo: steps towards cost effective vaccines.

Tacken PJ, Figdor CG. Tacken PJ, et al. Semin Immunol. 2011 Feb;23(1):12-20. doi: 10.1016/j.smim.2011.01.001. Epub 2011 Jan 26. Semin Immunol. 2011. PMID: 21269839 Review.

8

Multimodal imaging of nanovaccine carriers targeted to human dendritic cells.

Cruz LJ, Tacken PJ, Bonetto F, Buschow SI, Croes HJ, Wijers M, de Vries IJ, Figdor CG. Cruz LJ, et al. Among authors: tacken pj. Mol Pharm. 2011 Apr 4;8(2):520-31. doi: 10.1021/mp100356k. Epub 2011 Mar 16. Mol Pharm. 2011. PMID: 21381651 Free article.

9

The influence of PEG chain length and targeting moiety on antibody-mediated delivery of nanoparticle vaccines to human dendritic cells.

Cruz LJ, Tacken PJ, Fokkink R, Figdor CG. Cruz LJ, et al. Among authors: tacken pj. Biomaterials. 2011 Oct;32(28):6791-803. doi: 10.1016/j.biomaterials.2011.04.082. Epub 2011 Jul 2. Biomaterials. 2011. PMID: 21724247

10

Targeting DC-SIGN via its neck region leads to prolonged antigen residence in early endosomes, delayed lysosomal degradation, and cross-presentation.

Tacken PJ, Ginter W, Berod L, Cruz LJ, Joosten B, Sparwasser T, Figdor CG, Cambi A. Tacken PJ, et al. Blood. 2011 Oct 13;118(15):4111-9. doi: 10.1182/blood-2011-04-346957. Epub 2011 Aug 22. Blood. 2011. PMID: 21860028 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

37 results

Search Page

Filters